Table 2.
iPFS and OS according to subgroups
| n | Median iPFS (months) | 95% CI | P-value | Median OS (months) | 95% CI | P-value | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Gender | |||||||
| Male | 45 | 14.2 | 9.362–19.038 | 0.584 | 25.5 | 17.718–33.282 | 0.380 |
| Female | 59 | 15.1 | 13.683–16.517 | 28.0 | 21.150–34.850 | ||
| Age (years) | |||||||
| >60 | 37 | 17.6 | 11.421–16.579 | 0.649 | 28.3 | 21.815–34.785 | 0.326 |
| ≤60 | 67 | 14.0 | 13.037–22.163 | 25.5 | 29.575–31.425 | ||
| ECOG-PS | |||||||
| 0–1 | 92 | 14.5 | 11.291–17.709 | 0.952 | 25.4 | 20.760–30.040 | 0.198 |
| ≥2 | 12 | 14.5 | 4.316–24.684 | 25.5 | 2.705–48.295 | ||
| Symptomatic of BM | |||||||
| Yes | 36 | 17.6 | 13.787–21.413 | 0.218 | 28.0 | 24.122–31.878 | 0.953 |
| No | 68 | 14.0 | 10.780–17.220 | 25.4 | 19.988–30.812 | ||
| Smoking status | |||||||
| Never | 77 | 14.5 | 11.882–17.118 | 0.996 | 27.3 | 22.842–31.758 | 0.761 |
| Former | 27 | 16.1 | 9.124–23.076 | 25.5 | 16.953–34.047 | ||
| EGFR mutations | |||||||
| 19 del | 39 | 14.5 | 11.634–16.214 | 0.915 | 27.5 | 17.050–38.365 | 0.356 |
| L858R | 39 | 15.1 | 13.852–16.786 | 22.1 | 17.552–26.865 | ||
| Other | 26 | 17.2 | 12.466–21.756 | 28.2 | 23.678–32.986 | ||
| Extracranial metastasis initially | |||||||
| Yes | 83 | 14.5 | 11.031–17.969 | 0.362 | 24.0 | 18.579–29.421 | 0.203 |
| No | 21 | 15.1 | 6.179–24.021 | 28.4 | 24.543–32.257 | ||
| Number of BMs | |||||||
| >3 | 70 | 12.5 | 12.952–17.432 | 0.044 | 27.3 | 21.633–32.967 | 0.696 |
| ≤3 | 34 | 18.0 | 16.142–23.554 | 30.0 | 21.027–38.973 | ||
| Therapy method | |||||||
| EGFR-TKI plus WBRT | 56 | 17.7 | 16.288–22.212 | 0.015 | 28.1 | 23.975–32.225 | 0.756 |
| EGFR-TKI alone | 48 | 11.0 | 8.067–13.933 | 24.0 | 17.428–30.572 | ||
Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group Performance Status; iPFS, intracranial progression-free survival; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.